Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Jul;26(1):41–44. doi: 10.1111/j.1365-2125.1988.tb03361.x

Naproxen kinetics in synovial fluid of patients with osteoarthritis.

R Bruno 1, A Iliadis 1, I Jullien 1, M Guego 1, H Pinhas 1, S Cunci 1, J P Cano 1
PMCID: PMC1386497  PMID: 3203059

Abstract

1. The kinetics of naproxen in synovial fluid were studied in 407 osteoarthritic outpatients with knee effusion requiring aspiration, following a single 1100 mg oral dose of naproxen sodium. 2. The drug concentration-time profiles were described by a biexponential function. Naproxen entered synovial fluid rapidly, reaching a maximum concentration of 36 mg l-1 (Cmax) at 7.5 h. The first order input rate constant (kOs) was 0.41 +/- 0.15 h-1 with a lag time (tlag) of 0.24 +/- 0.36 h. 3. Elimination from the fluid was slow (t1/2 = 31 +/- 12 h) and appreciable drug concentrations were still measurable (27 mg l-1) after 24 h. 4. During once daily dosing of naproxen sodium, naproxen should accumulate in synovial fluid, a steady-state being achieved within a week of treatment. The predicted accumulation ratio based on trough concentration was 2.4.

Full text

PDF
41

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarons L., Salisbury R., Alam-Siddiqi M., Taylor L., Grennan D. M. Plasma and synovial fluid kinetics of flurbiprofen in rheumatoid arthritis. Br J Clin Pharmacol. 1986 Feb;21(2):155–163. doi: 10.1111/j.1365-2125.1986.tb05170.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Boxenbaum H. G., Riegelman S., Elashoff R. M. Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm. 1974 Apr;2(2):123–148. doi: 10.1007/BF01061504. [DOI] [PubMed] [Google Scholar]
  3. Iliadis A., Bruno R., Cano J. P. Steady-state dosage regimen calculations in linear pharmacokinetics. Int J Biomed Comput. 1986 May;18(3-4):167–182. doi: 10.1016/0020-7101(86)90014-0. [DOI] [PubMed] [Google Scholar]
  4. Jalava S., Saarimaa H., Anttila M., Sundquist H. Naproxen concentrations in serum, synovial fluid, and synovium. Scand J Rheumatol. 1977;6(3):155–157. doi: 10.3109/03009747709095441. [DOI] [PubMed] [Google Scholar]
  5. Netter P., Bannwarth B., Lapicque F., Harrewyn J. M., Frydman A., Tamisier J. N., Gaucher A., Royer R. J. Total and free ketoprofen in serum and synovial fluid after intramuscular injection. Clin Pharmacol Ther. 1987 Nov;42(5):555–561. doi: 10.1038/clpt.1987.196. [DOI] [PubMed] [Google Scholar]
  6. Runkel R., Chaplin M., Boost G., Segre E., Forchielli E. Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects. J Pharm Sci. 1972 May;61(5):703–708. doi: 10.1002/jps.2600610507. [DOI] [PubMed] [Google Scholar]
  7. Sheiner L. B. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev. 1984;15(1-2):153–171. doi: 10.3109/03602538409015063. [DOI] [PubMed] [Google Scholar]
  8. Wallis W. J., Simkin P. A. Antirheumatic drug concentrations in human synovial fluid and synovial tissue. Observations on extravascular pharmacokinetics. Clin Pharmacokinet. 1983 Nov-Dec;8(6):496–522. doi: 10.2165/00003088-198308060-00002. [DOI] [PubMed] [Google Scholar]
  9. van den Ouweland F. A., Franssen M. J., van de Putte L. B., Tan Y., van Ginneken C. A., Gribnau F. W. Naproxen pharmacokinetics in patients with rheumatoid arthritis during active polyarticular inflammation. Br J Clin Pharmacol. 1987 Feb;23(2):189–193. doi: 10.1111/j.1365-2125.1987.tb03028.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES